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Abstract
Background: CCCTC-binding factor (CTCF) is a conserved zinc finger transcription factor that is involved in both
intra- and interchromasomal looping. Recent research has shown a role for CTCF in estrogen receptor (ER) biology,
at some individual loci, but a multi-context global analysis of CTCF binding and transcription activity is lacking.
Results: We now map CTCF binding genome wide in breast cancer cells and find that CTCF binding is unchanged
in response to estrogen or tamoxifen treatment. We find a small but reproducible set of CTCF binding events that
overlap with both the nuclear receptor, estrogen receptor, and the forkhead protein FOXA1. These overlapping
binding events are likely functional as they are biased towards estrogen-regulated genes, compared to regions
lacking either CTCF or ER binding. In addition we identify cell-line specific CTCF binding events. These binding
events are more likely to be associated with cell-line specific ER binding events and are also more likely to be
adjacent to genes that are expressed in that particular cell line.
Conclusion: The evolving role for CTCF in ER biology is complex, but is likely to be multifunctional and possibly
influenced by the specific genomic locus. Our data suggest a positive, pro-transcriptional role for CTCF in ER-
mediated gene expression in breast cancer cells. CTCF not only provides boundaries for accessible and ‘protected’
transcriptional blocks, but may also influence the actual binding of ER to the chromatin, thereby modulating the
estrogen-mediated gene expression changes observed in breast cancer cells.
Background
Estrogen receptor alpha (ER), the driving transcription
factor of the majority of breast cancer tumors, is a
nuclear receptor that binds to the chromatin in order to
regulate transcription of its target genes, ultimately to
promote cell proliferation. ER most frequently binds to
enhancer regions and rarely to promoter regions [1,2],
and ER binding to the chromatin has been shown to
require the pioneer factor, FOXA1 [2-5]. In addition to
the pioneering function of FOXA1 for interaction with
condensed chromatin, ER also requires a host of cofac-
tors in order to regulate gene transcription of its target
genes. Transcription involves chromatin loops that form
between ER bound to enhancer regions and promoter
regions of target genes [6,7].
There has been recent interest in understanding the
possible role of the insulator protein, CCCTC-binding
factor (CTCF) in ER biology. CTCF is a highly con-
served and abundant zinc-finger protein that is ubiqui-
tously expressed in the majority of tissue types. It is a
large protein including 11 zinc fingers which it uses to
bind to the DNA. CTCF was originally identified as a
transcription factor that binds to the mammalian and
avian MYC promoter [8-10]. More recently many differ-
ent roles have been attributed to CTCF: it has now been
identified as a transcriptional activator [11], a transcrip-
tional repressor [8], a transcription factor involved in
hormone-responsive gene silencing [12,13], an insulator
protein [14], a protein involved in imprinting [15] and
X-chromosome inactivation [16] as well as a participant
in long-range chromatin interactions, both within and
between chromosomes [17].
As the binding profiles of CTCF and ER have now
been published [1,2,5,18-22], several studies have endea-
voured to understand potential interactions between
CTCF and ER. Initially, computational methods were
employed to describe the global pattern of ER and
CTCF binding events [23]. Chan and Song proposed
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that CTCF binding partitions the genome into ER-regu-
latory blocks that contain ER binding events and estro-
gen-regulated genes. This initial observation was
validated on the TFF1 locus, which showed that CTCF
can demarcate regions of the genome that are respon-
sive to estrogen treatment [24]. Two CTCF binding
events flanking the TFF1 locus were shown to act as
boundary elements by preventing the spread of hetero-
chromatin and allowing the genes within this region to
be estrogen regulated.
It is currently unknown what the global role of CTCF
is in estrogen and tamoxifen-mediated gene transcrip-
tion in breast cancer cells. We show on a genome-wide
scale that CTCF binding is static in breast cancer cells
in response to estrogen or tamoxifen treatment. We
show that CTCF co-localises with key transcription fac-
tors in breast cancer cell lines and that these co-bound
regions are likely to be functional. We identify cell-line
specific CTCF binding events in different breast cell
lines; these cell-line unique CTCF binding events are
associated with genes that are highly expressed in that
cell line.
Results and discussion
CTCF binding is static in response to estrogen or
tamoxifen treatment
CTCF is a ubiquitously expressed protein that has
been well documented to act as an insulator protein
and prevent looping between enhancers and promoters
[14,25]. Previous reports have demonstrated that loop-
ing between ER and promoters of estrogen-regulated
genes is required for estrogen-mediated transcription
of target genes [6,7,26]. We therefore hypothesised
that CTCF binding may play a role in regulating ER
gene transcription by preventing transcription of estro-
gen target genes in the presence of tamoxifen. To test
this hypothesis, MCF-7 cells were hormone deprived
for three days and then treated with vehicle, 100 nM
estrogen or 1 μM tamoxifen for 45 minutes and three
hours. Genome-wide CTCF chromatin immunoprecipi-
tation followed by sequencing (ChIP-seq) was per-
formed; in all treatments and time points at least
seven million aligned reads were obtained (Additional
File 1). Peaks were called using MACS [27] and at
least 56, 342 CTCF binding events could be identified
across the genome in all the samples (Additional File
1). The overlap between the samples was at least 91%
and no reproducible differences were observed in the
different treatment conditions (Figure 1A and 1B) at
any of the time points. Genomic distribution analysis
showed that CTCF binding in MCF-7 cells occurred
mostly at intergenic and intronic regions, with only
5.7% CTCF binding events occurring within 1 kb of
promoters (Figure 1C).
CTCF binding has previously been shown to separate
the genome into different blocks, some which contain
ER binding regions and ER-regulated genes, and some
which do not [23]. Similar patterns were observed in
this study (Additional File 2) suggesting that CTCF may
be required at these regions to demarcate the estrogen-
responsive genes within the chromatin.
CTCF binding can co-localise with ER and FOXA1 binding
As the CTCF motif has previously been shown to be
enriched in ER binding regions [28], we asked whether
CTCF binding in MCF-7 cells overlaps with ER binding.
In addition, we assessed whether CTCF binding overlaps
with the pioneer factor FOXA1, which has been shown
to be required for ER binding to the chromatin and pro-
liferation of ER-positive cells [2-5]. As we have shown
that CTCF binding does not change with estrogen or
tamoxifen treatment, CTCF binding in hormone-
deprived, vehicle-treated MCF-7 cells was used for the
analysis. Considering peaks that were called in both
replicates, 55, 176 CTCF binding events could be identi-
fied across the genome. ER binding was also mapped in
Figure 1 CTCF binding does not change in response to
estrogen or tamoxifen treatment. CTCF binding was mapped by
ChIP-seq in MCF-7 cells treated with vehicle, 100 nM estrogen or 1
μM tamoxifen for 45 minutes and 3 hours. A. Heat map
representing CTCF binding intensity in MCF-7 cells treated with
vehicle, estrogen or tamoxifen for 45 minutes. The window
represents -/+ 5 kb regions from the centre of the CTCF binding
events. B. Examples of genomic loci showing CTCF binding in
vehicle-, estrogen- and tamoxifen-treated MCF-7 cells. C. Global
genomic distribution of CTCF binding events in MCF-7 cells.
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proliferating MCF-7 cells, in duplicate, resulting in 57,
662 ER binding events (Additional File 1). For the
FOXA1 binding data, a previously published dataset was
used that identified 79, 624 FOXA1 binding events in
vehicle-treated MCF-7 cells [5]. The FOXA1 ChIP-seq
was conducted and analysed in exactly the same way as
the CTCF and ER ChIP-seq data.
Using the definition that a binding region must occur
in both replicates, overlapping by at least one base pair,
almost a third (29%, 14, 040/48, 037) of CTCF binding
events co-localised with ER and/or FOXA1 (Figure 2A),
with the majority (9, 431/14, 040) of these co-localised
binding regions consisting of FOXA1 and CTCF bind-
ing, but not ER binding. The probability of this overlap
occurring by chance is p ≈ 0 using the GSC method
[29,30]. Interestingly, when considering the 2, 301 geno-
mic loci bound by CTCF, ER and FOXA1, the binding
of ER and FOXA1 did not necessarily occur directly
over the CTCF binding summit, but did occur within 1
kb of the CTCF binding summit (Figure 2B). Due to the
non-centred nature of the ER and FOXA1 binding in
the heat map and intensity plot, the ER and FOXA1
binding appear weaker in the regions bound by CTCF/
ER/FOXA1. However, the normalised sum of the inten-
sities of CTCF, ER and FOXA1 binding, in regions co-
bound by all three factors, was 190, 782, 252, 928 and
137, 374, respectively, showing that ER binding intensity
at these regions is not weaker than CTCF binding.
To determine whether ER and FOXA1 are binding
directly to the DNA at regions co-bound by CTCF, ER
and/or FOXA1, motif analysis was performed. The data
shows that regions bound by CTCF/ER/FOXA1 are
enriched for estrogen response elements (ERE), CTCF
and forkhead motifs, suggesting that all three proteins
bind to the DNA at these regions (Figure 2D). Similarly,
regions bound by ER/CTCF were significantly enriched
for ERE and CTCF motifs, and regions bound by
FOXA1/CTCF were enriched for CTCF and forkhead
motifs, although the enrichment of these motifs was not
significant using this stringent motif analysis. In regions
only bound by CTCF/FOXA1 but not ER, no enrich-
ment for ERE motifs was detected and in regions bound
by only CTCF/ER, no forkhead motifs were enriched.
Interestingly, the ERE motifs were enriched in a large
window surrounding the summit of the peaks, especially
in the ER/CTCF co-bound regions. This is in line with
the ER binding data that is not centred over the CTCF
binding summit. The only other motifs that were statis-
tically enriched in these categories were MYF, znf143
and PPARG, although it is currently unclear what the
significance of these motifs is.
To determine whether these observations were unique
to MCF-7 cells, CTCF and ER binding were mapped in
another ER-positive cell line, ZR75-1. ChIP-seq was per-
formed in duplicate for both factors and at least 19 mil-
lion mapped reads were obtained per library (Additional
File 1). Considering peaks that were called in both repli-
cates, 41, 683 ER binding events and 48, 898 CTCF
binding events could be identified in the ZR75-1 cells.
Previously published data reporting 74, 670 FOXA1
binding events in ZR75-1 cells was also used [5]. Over-
lapping of the datasets revealed 4, 023 regions bound by
ER/FOXA1/CTCF or ER/CTCF or FOXA1/CTCF
(Additional File 3). The majority (60%) of the 4, 023
regions co-bound in the ZR75-1 cell line were also co-
bound in the MCF-7 cell line, perhaps indicating a con-
served function.
Genomic location analysis in the MCF-7 cell line
revealed the striking result that 21.7% of the ER/CTCF
regions were located within 1 kb upstream of transcrip-
tional start sites. This differs from a normal ER binding
profile as ER binds predominantly in enhancer regions
and rarely at promoter regions (< 5% ER binding events
Figure 2 CTCF binding can co-localise with ER and/or FOXA1 in
MCF-7 cells. CTCF, ER and FOXA1 binding profiles in MCF-7 cells
were analysed. A. Heat map showing clustered binding signal for
ER, FOXA1 and CTCF binding in MCF-7 cells. The heat map shows
regions co-bound by ER/FOXA1/CTCF, or ER/CTCF or FOXA1/CTCF.
The window represents -/+ 5 kb regions from the centre of the
CTCF binding events. B. The sum of the normalised binding
intensity profile of CTCF, ER and FOXA1 in regions co-bound by all
three factors is shown. C. Two examples of genomic loci bound by
CTCF, ER and FOXA1 in MCF-7 cells. D. Heat maps showing
enriched motifs (the p values are shown) in regions bound by CTCF
together with ER and/or FOXA1.
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are within 1 kb promoter regions) [1,2]. Furthermore,
11.4% of the ER/FOXA1/CTCF bound regions were
located within one kb of promoter regions. However,
the CTCF unique and FOXA1/CTCF regions displayed
a normal CTCF genomic distribution with about 5% of
binding events occurring within 1 kb promoter regions.
The genomic distribution analysis of the ZR75-1 data
differed in that all the different categories displayed a
normal CTCF distribution, with between 3 and 5.6% of
the CTCF binding events occurring at promoter regions.
CTCF and ER co-bound regions are enriched near
estrogen-regulated genes, compared with regions lacking
either one
To determine whether the regions bound by CTCF/ER
and/or FOXA1 are likely to be functional and involved in
regulating gene transcription, the binding data in MCF-7
was overlapped with a previously published gene expression
dataset that identified genes that are up or down regulated
after estrogen stimulation [1]. In order to assess the direct
transcriptional effects of ER, early time points were used
for the analysis, namely three and six hours after estrogen
treatment. Any genes that significantly changed (p < 0.01)
at either time point were included in the analysis. This
resulted in the identification of 1, 608 estrogen-upregulated
genes, and 1, 350 estrogen-downregulated genes. As ER
most often binds to enhancer regions, a 20 kb window on
either side of the transcriptional start site of the genes was
assessed for CTCF, ER and FOXA1 binding events (a 20 kb
window has been previously identified from cell line experi-
ments as an appropriate window between ER binding
events and regulated genes [31]).
Results showed that regions bound by ER and CTCF
were, on the whole, more likely to be near estrogen-
regulated genes, and specifically estrogen-downregulated
genes, when compared with regions bound by either
one (Figure 3). ER/FOXA1/CTCF binding events were
also significantly biased towards estrogen-regulated
genes, compared to ER/FOXA1 binding events that do
not have an overlapping CTCF binding event. These
results suggest that CTCF can mark euchromatic
regions, which may allow ER to bind and then activate
or repress expression of its target genes. Surprisingly,
regions bound by ER and FOXA1, but not CTCF, were
least likely to be near estrogen-regulated genes.
CTCF can bind uniquely in breast cell lines
As some CTCF binding events overlap with ER and
FOXA1 binding events, we assessed whether the CTCF
binding profile in an ER-negative cell line, lacking ER and
FOXA1 expression, would differ. In order to determine
this, CTCF ChIP-seq was performed in the ER-negative
breast cell line MCF10A, originally generated from a
woman with fibrocystic disease [32]. CTCF was mapped,
in duplicate, in MCF10A cells; this resulted in the identi-
fication of 39, 995 CTCF-bound genomic loci (Additional
File 1). Analysis showed that the majority of CTCF bind-
ing events were shared between all three interrogated cell
lines and that these common CTCF binding events were
generally the strongest bound regions (Figure 4A). How-
ever, reproducible differences in CTCF binding among
the three breast cell lines were observed (Figure 4A).
A cell-line specific CTCF binding event was defined as
a peak identified in both replicates of that cell line and
in neither replicate of the other cell lines. This resulted
in 7, 314 MCF-7-specific CTCF binding events, 2, 730
ZR75-1-specific CTCF binding events, and 1, 037
MCF10A-specific CTCF binding events (Figure 4A).
Examples of these are shown in Figure 4B. In addition,
4, 858 CTCF binding events were identified in both ER-
positive cell lines, but not the ER-negative MCF10A cell
line (Figure 4A). This overlap is higher than the number
of CTCF binding events that were common to only one
of the ER-positive cell lines and the ER-negative cell line
(795 CTCF binding regions shared between MCF-7 and
MCF10A and 1, 354 CTCF binding events shared
between ZR75-1 and MCF10A), suggesting a link
between CTCF and ER binding.
Figure 3 CTCF/ER bound regions are more likely to be near
estrogen-regulated genes. Genomic regions bound by ER/FOXA1/
CTCF, ER/CTCF, FOXA1/CTCF or regions bound by ER and FOXA1,
but not CTCF, were analysed to determine whether they were
enriched near estrogen-regulated genes. Genes that are up- or
down-regulated by estrogen within six hours of estrogen treatment
were included. The percentage of binding events +/- 20 kb from an
estrogen up- or down-regulated gene was assessed. Graph showing
the percentage of binding events in the different classes that are
-/+ 20 kb from estrogen up- or down-regulated genes. Included as
a control are binding events that overlap between ER and FOXA1
binding but do not overlap with CTCF binding. ** denotes p < 2.5
× 10-5
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On the whole, the cell-line specific CTCF binding
events were weaker than the common CTCF binding
events, but they were reproducible and therefore may
contribute to cell-line specific gene expression. Motif
analysis was performed on the cell-line unique CTCF
binding events to determine if there were any differ-
ences in enriched motifs in the cell-line unique CTCF
binding events. In the common CTCF binding events,
the CTCF motif was the only motif that was enriched.
However, the cell-line specific CTCF binding events in
all cell lines were enriched for the MYF motif (Addi-
tional File 4). The MCF10A-specific CTCF binding
regions also showed enrichment for AP-1 and TAL1:
TCF3 motifs. The function of these potential binding
sites is unknown, but suggests a role for MYF and AP-1
transcription factors in CTCF function.
Cell-line specific CTCF binding is more likely to overlap
with cell-line specific ER binding
ER binding profiles differ in different breast cancer cell
lines [5]. This may be due to different ER protein levels,
different phosphorylation of ER or differences in cofac-
tor levels within the cell lines. In this study we found
23, 472 ER binding events were shared between MCF-7
and ZR75-1 cells (i.e. peaks called in both replicates in
both cell lines), 25, 986 ER binding events were specific
to MCF-7 cells (peaks called in both MCF-7 replicates
and none of the ZR75-1 replicates) and 13, 908 ER
binding events could only be identified in ZR75-1 cells
(called in both ZR75-1 replicates and none of the MCF-
7 replicates) (Figure 5). This shows that only 50 to 60%
of ER binding events are shared between two ER-posi-
tive cells lines, and generally the overlapping ER binding
events are the stronger ER binding events. MCF10A
does not express ER and was therefore not included in
this analysis.
If CTCF and ER are interacting co-operatively, the
cell-line unique CTCF binding events would be more
likely to overlap with the cell-line unique ER binding
events. We assessed this by overlapping the cell-line
unique CTCF binding events with the cell-line unique
ER binding events. A larger overlap (8.5%) between
MCF-7-specific CTCF and MCF-7-specific ER binding
was observed, compared to the overlap between ZR75-
1-specific CTCF binding and MCF-7-specific ER binding
(0.1%) (Figure 5). Additionally, ZR75-1-specific CTCF
Figure 4 CTCF can bind uniquely in different breast cell lines.
CTCF binding was mapped in two ER-positive breast cancer cell
lines (MCF-7 and ZR75-1) as well as an ER-negative breast cell line
(MCF10A). A. Heatmap showing CTCF binding profiles in MCF-7,
ZR75-1 and MCF10A cells. CTCF binding events that are shared
between all three cell lines (I), that are present in only the ER-
positive MCF-7 and ZR75-1 cells (II), as well as CTCF binding events
are unique to MCF-7 (III) or ZR75-1 (IV) or MCF10A cells (V) are
shown. The window represents -/+ 5 kb regions from the centre of
the CTCF binding events. B. Examples of genomic regions that are:
I, common CTCF binding events, II: CTCF binding events present in
ER-positive cell lines only, III: MCF-7 unique, IV: ZR75-1 unique, and
V: MCF10A-unique CTCF binding events.
Figure 5 Cell-line unique CTCF binding events are more likely
to overlap with cell-line specific ER binding events. ER binding
was mapped in MCF-7 and ZR75-1 cells using ChIP-seq. Heatmap
showing MCF-7- and ZR75-1-unique ER binding events. The window
represents -/+ 5 kb regions from the centre of the ER binding
events. Shared ER binding events, as well as MCF-7 and ZR75-1
unique ER binding events were overlapped with CTCF binding
events that were unique to MCF-7, ZR75-1 or MCF10A cells as well
as CTCF binding events that were shared between all three cell
lines (Common CTCF). Percentage overlaps are shown.
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binding events were more likely to overlap with ZR75-1-
specific ER binding events (5.6%) compared to the other
cell-line specific CTCF binding events (0.1% for MCF-7
specific and 0.2% for MCF10A-specific CTCF binding
events) (Figure 5). These data suggest that cell-line spe-
cific CTCF and ER binding may be functionally related.
Cell-line unique CTCF binding events are likely to be
functional
We asked whether at least some cell line specific CTCF
binding events are functional. Although it is difficult to
test globally whether ChIP-seq peaks are functional, we
hypothesized that if they are, their genomic location
should be biased towards genes that are differentially
regulated in the corresponding cell line, with respect to
other cell lines. To test this hypothesis, we performed
gene expression analysis of proliferating MCF-7, ZR75-1
and MCF10A cells, and compared the differentially
expressed (DE) genes in each cell line with cell-line spe-
cific CTCF binding events.
For each cell line, a list of candidate genes was con-
structed of genes that were DE in that cell line with
respect to both other cell lines (p < 0.01), but not DE
between the other two cell lines. This resulted in 2, 503,
2, 140 and 2, 306 genes being included in the analysis
for MCF10A, MCF-7 and ZR75-1, respectively. Lists of
genes within 20 kb of cell-line unique CTCF peaks were
constructed, with 438, 436 and 534 genes found for
MCF10A, MCF-7 and ZR75-1, respectively. Fisher’s
exact test was performed to determine whether DE
genes were over-represented in the lists of genes near
CTCF peaks. Table 1 shows the results of the tests.
Table 1 shows that genes DE in MCF10A are very sig-
nificantly associated with MCF10A-specific CTCF peaks,
but genes DE only in MCF-7 or ZR75-1 are not signifi-
cantly associated with these peaks. Similarly, genes DE
in ZR75-1 cells are significantly associated with CTCF
peaks unique to those cells, while genes DE in the other
cell lines are not. Unexpectedly, all three cell lines
showed a pattern of DE genes being associated with
MCF-7 unique peaks. However, the odds ratio for the
MCF-7 genes was higher than for the other two cell
lines (1.777 for MCF-7 versus 1.558 and 1.565 for
MCF10A and ZR75-1), so it is still arguably the case
that MCF-7 DE genes are preferentially associated with
MCF-7 unique CTCF sites. It may be that the large
number of MCF-7 unique CTCF sites simply means
that by chance, many genes in each cell line are near at
least one site. These results demonstrate that the cell-
line unique CTCF binding events are statistically biased
towards genes that are differentially expressed in that
cell line, suggesting that the CTCF unique sites are
functional and are modifying the chromatin to influence
gene transcription.
CTCF is a highly conserved protein that has many dif-
ferent roles in a cell. In this study an additional role for
CTCF as a transcriptional regulator, in combination
with the steroid receptor ER, and the pioneer factor
FOXA1, is described. CTCF has previously been shown
to be required for hormone-responsive silencing of tar-
get genes, together with the nuclear receptors, thyroid
hormone receptor and retinoic acid receptor [12,13]. In
these studies, mutation of the CTCF binding motif
resulted in genes no longer being repressed in response
to ligand, indicating that CTCF is required for hor-
mone-responsive silencing of target genes. At these
regions it was shown that CTCF was required to recruit
corepressors, such as Sin3A and histone deacetylases, in
order to silence expression of the target genes [33]. Our
study now shows that regions bound by ER and CTCF
are enriched near estrogen-regulated genes, and espe-
cially estrogen down-regulated genes. It is possible that
CTCF is playing a similar role together with ER, and
that CTCF is required to recruit co-repressors in order
to silence gene transcription in response to estrogen
treatment.
Interestingly, the CTCF and thyroid response elements
responsible for the synergistic gene silencing between
CTCF and thyroid hormone receptor are separated by
160 base pairs [12]. This is similar to what was observed
in this study, as the ER, FOXA1 and CTCF binding
peaks do not overlap perfectly, but rather, may be
shifted to one side. Thus far, CTCF has not been shown
to interact directly with the thyroid hormone receptor
Table 1 Cell-line unique CTCF binding events are biased towards genes that are differentially regulated in the
corresponding cell line, with respect to other cell lines.
Genes adjacent to cell-line unique CTCF peaks
Genes Differentially Expressed MCF10A MCF-7 ZR75-1
MCF10A p = 4.652e-14 p < 2.2e-16 p = 0.5983
MCF-7 p = 0.06637 p < 2.2e-16 p = 0.4189
ZR75-1 p = 0.5536 p < 2.2e-16 p = 0.002955
The number of genes differentially expressed in each cell line, with respect to both other cell lines, but not in the other cell lines with respect to each other; the
number of genes within 20 kb of a cell-line specific CTCF binding site; and the p-values from Fisher’s exact test of the overlaps between those sets. The universe
of genes is the 24, 928 distinct genes present on the Illumina gene expression arrays used in the experiment.
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in in vitro pull down assays [12]. This may be due to
technical issues or perhaps an additional protein is
required in the interaction between CTCF and thyroid
hormone receptor. Likewise, it remains to be deter-
mined whether ER, FOXA1 and CTCF interact directly
or form part of the same complex. As the ER, FOXA1
and CTCF motifs are so clearly enriched in the various
categories, it seems likely that these factors bind directly
to the DNA and co-operate to regulate target genes.
It has been shown that CTCF binding to target sites
flanking the TFF1 locus form a chromatin loop and are
required for the TFF1 locus to be estrogen responsive
[24]. This study has identified additional estrogen-regu-
lated genes, namely XBP1, GREB1 and NRIP1, that may
require CTCF binding to demarcate the estrogen-respon-
sive regions and allow the genes to be estrogen regulated.
It is possible that CTCF acts as a barrier insulator at
these regions to prevent the spreading of heterochroma-
tin. At other specific regions, CTCF may negatively affect
the binding potential of FoxA1 [5]. In addition, a small
percentage of genomic regions bound by ER/FOXA1/
CTCF (150 out of 2, 301) or ER/CTCF (93 out of 2, 308)
are involved in ER chromatin loops [31], supporting the
idea that CTCF can form loops together with ER to
demarcate estrogen-responsive regions in the genome.
As CTCF binding is not responsive to estrogen or
tamoxifen in MCF-7 cells and occurs in the absence of
estrogen treatment, CTCF must bind to the chromatin
independently of ER. As cell-line specific CTCF binding
events are more likely to overlap with cell-line specific
ER binding events, CTCF may direct ER binding at
these regions thereby acting as a ‘licensing factor’ for
ER. This hypothesis is supported by Zhang et al., who
showed that FOXA1 binding, and therefore presumably
ER binding, was dependent on CTCF binding to the
TFF1 locus [24]. Adding another level of complexity,
previous studies have demonstrated that multiple
nucleosome position sites within the chromatin are
required to direct nucleosome positioning [34,35]. These
nucleosome position patterns are necessary for CTCF to
bind to insulator regions. It may be thus hypothesised
that nucleosome position sites within the genome direct
where CTCF binds, which further directs where the pio-
neer factor FOXA1 binds, ultimately regulating binder
binding to the chromatin.
Conclusions
The evolving role for CTCF in ER biology is complex,
but is likely to be multifunctional and possibly influ-
enced by the specific genomic locus. Our data suggests
that CTCF not only provides boundaries for accessible
and ‘protected’ transcriptional blocks, but may also
influence the actual binding of ER to the chromatin,
thereby modulating the estrogen-mediated gene expres-
sion changes observed in breast cancer cells.
Methods
Cell culture
MCF-7 cells were grown in DMEM containing 10%
heat-inactivated FBS, 2 mM L-glutamine, 50 U/ml peni-
cillin and 50 μg/ml streptomycin and ZR75-1 cells were
grown in RPMI containing 10% heat-inactivated FBS, 2
mM L-glutamine, 50 U/ml penicillin and 50 μg/ml
streptomycin. MCF10A cells were maintained in Mam-
mary Epithelium Cell Growth Medium bullet kit (Clo-
netics, Lonza, MD, USA), containing mammary
epithelium basal medium supplemented with bovine
pituitary extract, human epidermal growth factor, hydro-
cortisone and GA-1000 (Gentamicin Sulfate and
Amphotericin-B). All cells were genotyped to ensure
their identity using short tandem repeat (STR) PCR. To
hormone deprive the cells, cells were grown in steroid-
depleted medium for three days and then treated with
vehicle (ethanol), 100 nM estrogen or 1μM tamoxifen
for 45 minutes and three hours.
Chromatin immunoprecipitations
The antibodies used were anti-ER (sc-543) from Santa
Cruz Biotechnologies and anti-CTCF (07-729) from
Millipore. At least four 15 cm dishes of cells were used
per chromatin immunoprecipitation (ChIP) and samples
were processed according to standard ChIP procedures
[36]. The immunoprecipitated DNA was subsequently
amplified as previously described for Illumina sequen-
cing [36].
High-throughput sequencing and enrichment analysis
Sequences generated by the Illumina genome analyzer
were aligned against NCBI Build 36.3 of the human
genome using MAQ http://maq.sourceforge.net/ with
default parameters. Peaks were called using Model-
based Analysis for ChIP-Seq (MACS) [27], run using
default parameters (except mfold = 30). Data was
further analysed using the web-based tool, Galaxy
[37].
Heat map generation
To generate the heat maps of the raw ChIP-sequencing
(ChIP-seq) data, CTCF or ER binding peaks were used
as targets to centre each window. Each window was
divided into 100 bins of 100 bp in size. An enrichment
value was assigned to each bin by counting the number
of sequencing reads in that bin and subtracting the
number of reads in the same bin of an input library.
Each data set was normalised to 10 million reads. Data
were visualized with Treeview [38].
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Structural correction analysis
To determine whether the overlap between transcription
factors (ER, CTCF and FOXA1) was statistically signifi-
cantly higher than expected by random chance, we
applied the genome structural correction statistic of
Bickel et al. [29,30]. This conservative statistic takes into
account the structure of bound regions across the gen-
ome in assessing the significance of overlaps. All com-
parisons had a p-value of approximately 0 with 10, 000
sampling iterations, so we reject the null hypothesis that
the transcription factors’ binding sites are unrelated, and
conclude that their overlap is statistically significant.
Motif analysis
Two kilobases of sequence surrounding the summit
positions were retrieved for each summit set. For each
set, the number of matches to a position weight matrix
(PWM) with a similarity score of 85% or more was
counted in 100 bp non-overlapping windows across the
2 kb regions on both strands. To determine if the num-
ber of PWM matches was significant, 1, 000 randomly
permuted versions of the matrix were generated and
matches were counted in each window on both strands.
The random matrix hits were used to generate a distri-
bution from which an empirical p-value was calculated
for each window. Specifically the area under a gaussian
density curve for values greater than or equal to the
number of PWM matches for the original matrix was
calculated. This procedure was repeated for each of the
476 PWM in the JASPAR_CORE_2009 collection.
Genomic location
Genomic location analysis was performed using CEAS
http://ceas.cbi.pku.edu.cn/.
Gene expression analysis
Total RNA was collected from proliferating cells and
RNA was hybridised to Illumina arrays. The Illumina
BeadChip (HumanWG-6 v3) bead-level data was pre-
processed, log2 transformed and quantile normalised
using the beadarray package in Bioconductor. Differen-
tial expression analysis was performed using the eBayes
measure from the limma R package [39] with a Benja-
mini & Hochberg multiple test correction procedure
[40] to identify statistically significant differentially
expressed genes (adjusted p-value < 0.01).
Statistics
p values were computed using the Chi squared test and
the two-tailed students t test using excel, as well as the
Fisher’s exact test [41].
Data accession
Data for the ChIP-seq experiments are deposited under
ArrayExpress accession number E-MTAB-740.
Reviewer Username: Reviewer_E-MTAB-740, Reviewer
Password: tGG21ssp
Data for the gene expression microarrays are depos-
ited under ArrayExpress accession number E-MTAB-
739.
Reviewer Username: Reviewer_E-MTAB-739, Reviewer
Password: ryLB299a
Additional material
Additional file 1: Illumina sequencing data for all samples included
in this study. CTCF or ER ChIP-sequencing was performed on the
different cell lines. Detailed include the number of filtered reads as well
as the number of peaks identified using MACS.
Additional file 2: CTCF binding demarcates estrogen-regulated
genes. CTCF and ER binding profiles were mapped by ChIP-sequencing
in MCF-7 cells. Examples of three classic estrogen-regulated genes, where
ER binding events that regulate expression of the genes are flanked by
CTCF binding events, are shown. A. The XBP1 genomic locus. B. The
NRIP1 genomic locus. C. The GREB1 genomic locus.
Additional file 3: CTCF binding can co-localise with ER and/or
FOXA1 in ZR75-1 cells. CTCF, ER and FOXA1 binding profiles in ZR75-1
cells were analysed. A. Heatmap showing clustered binding signal for ER,
FOXA1 and CTCF binding in the ZR75-1 cell line. The heatmap shows
regions co-bound by ER/FOXA1/CTCF, or ER/CTCF or FOXA1/CTCF. The
window represents -/+ 5 kb regions from the centre of the binding
events. B. Two examples of genomic loci bound by ER, FOXA1 and CTCF
in ZR75-1 cells. C. Heatmaps showing enriched motifs (p values are
shown) in regions bound by CTCF together with ER and/or FOXA1.
Additional file 4: Motif analysis was performed on the different
categories of CTCF binding events. Heatmaps showing enriched
motifs (p values are shown) in the CTCF binding events that are
common or unique to the different cell lines.
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